Travere Therapeutics (NASDAQ:TVTX) Insider William Rote Sells 112,850 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider William Rote sold 112,850 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $63.33, for a total transaction of $7,146,790.50. Following the transaction, the insider owned 98,197 shares in the company, valued at $6,218,816.01. The trade was a 53.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Up 2.0%

Shares of NASDAQ:TVTX opened at $64.74 on Friday. The company has a debt-to-equity ratio of 24.58, a quick ratio of 3.99 and a current ratio of 4.05. Travere Therapeutics, Inc. has a 52-week low of $22.06 and a 52-week high of $68.73. The business’s 50 day simple moving average is $61.63 and its two-hundred day simple moving average is $48.50. The firm has a market cap of $6.10 billion, a P/E ratio of -140.74 and a beta of 1.05.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03. The company had revenue of $169.58 million for the quarter, compared to analysts’ expectations of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.Travere Therapeutics’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same period last year, the business earned $0.13 EPS. As a group, research analysts forecast that Travere Therapeutics, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Travere Therapeutics by 53.4% during the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after purchasing an additional 211 shares during the last quarter. Fifth Third Bancorp bought a new position in shares of Travere Therapeutics during the 1st quarter worth approximately $35,000. Allworth Financial LP bought a new position in shares of Travere Therapeutics during the 2nd quarter worth approximately $47,000. Integrated Wealth Concepts LLC purchased a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $70,000. Finally, IFP Advisors Inc boosted its stake in shares of Travere Therapeutics by 11,770.0% in the 4th quarter. IFP Advisors Inc now owns 2,374 shares of the company’s stock worth $91,000 after buying an additional 2,354 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TVTX. Citigroup lifted their price objective on shares of Travere Therapeutics from $70.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Wells Fargo & Company raised their price target on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research report on Friday, June 12th. Canaccord Genuity Group lifted their price target on Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim boosted their price objective on Travere Therapeutics from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, HC Wainwright increased their price objective on Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $68.00.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.